Mainz Biomed BV (MYNZ)

[Mrogers23]

Mainz Biomed has laid the groundwork in 2022 for what could be a transformative 2023. That means from a market cap perspective, its roughly $98 million level could be undervaluing much of the progress made last year. In fact, current valuations could be considered accurate if just historical evidence provided the model's input. But that's not the case. There's plenty of forward-looking considerations contributing to MYNZ's case of deserving a more appropriate and higher valuation. https://www.benzinga.com/pressreleases/23/02/ab31084658/mainz-biomeds-milestones-reached-in-2022-can-be-catalysts-in-1h-2023-heres-why-mynz